Terms: = Bone cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
343 results:
1. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
2. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mtor signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
3. Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.
Wang Y; Ma X; Xu E; Huang Z; Yang C; Zhu K; Dong Y; Zhang C
Clin Transl Med; 2024 Feb; 14(2):e1586. PubMed ID: 38372422
[TBL] [Abstract] [Full Text] [Related]
4. Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo.
Kong Y; Li X; Zhang H; Fu B; Jiang HY; Yang HL; Dai J
Cell Death Dis; 2024 Jan; 15(1):57. PubMed ID: 38228583
[TBL] [Abstract] [Full Text] [Related]
5. Soy isoflavones induces mitophagy to inhibit the progression of osteosarcoma by blocking the AKT/mtor signaling pathway.
Zheng Z; Zhao X; Yuan B; Jiang S; Yan R; Dong X; Yao Q; Liang H
Mol Med; 2024 Jan; 30(1):5. PubMed ID: 38191316
[TBL] [Abstract] [Full Text] [Related]
6. Solute carrier family 35 member A2 regulates mitophagy through the PI3K/AKT/mtor axis, promoting the proliferation, migration, and invasion of osteosarcoma cells.
Luo X; Zhang J; Guo C; Jiang N; Zhang F; Jiao Q; Xu K; Yang J; Qu G; Lv XB; Zhang Z
Gene; 2024 Mar; 898():148110. PubMed ID: 38151177
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
8. Total flavonoids of Litchi chinensis Sonn. seed inhibit prostate cancer growth in bone by regulating the bone microenvironment via inactivation of the HGFR/NF-κB signaling pathway.
Zhang W; Chen T; Yang P; Li X; Zhu D; Su Z; Yang X; Jin R; Lan T; Guo H
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117327. PubMed ID: 37871755
[TBL] [Abstract] [Full Text] [Related]
9. RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K/AKT/mtor pathway.
Wei Z; Xia K; Zheng D; Gong C; Guo W
Mol Med; 2023 Oct; 29(1):133. PubMed ID: 37789274
[TBL] [Abstract] [Full Text] [Related]
10. Programmable DNA hydrogel provides suitable microenvironment for enhancing autophagy-based therapies in intervertebral disc degeneration treatment.
Qingxin S; Kai J; Dandan Z; Linyu J; Xiuyuan C; Yubo F; Kun W; Yingchao H; Hao C; Jie S; Zhi C; Hongxing S
J Nanobiotechnology; 2023 Sep; 21(1):350. PubMed ID: 37759249
[TBL] [Abstract] [Full Text] [Related]
11. Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mtor pathway.
Sim I; Choe W; Ri J; Su H; Moqbel SAA; Yan W
Med Oncol; 2023 Sep; 40(10):294. PubMed ID: 37668818
[TBL] [Abstract] [Full Text] [Related]
12. Single-cell transcriptomics reveals multiple chemoresistant properties in leukemic stem and progenitor cells in pediatric AML.
Zhang Y; Jiang S; He F; Tian Y; Hu H; Gao L; Zhang L; Chen A; Hu Y; Fan L; Yang C; Zhou B; Liu D; Zhou Z; Su Y; Qin L; Wang Y; He H; Lu J; Xiao P; Hu S; Wang QF
Genome Biol; 2023 Aug; 24(1):199. PubMed ID: 37653425
[TBL] [Abstract] [Full Text] [Related]
13. The Targeted Therapies for Osteosarcoma
Wang S; Ren Q; Li G; Zhao X; Zhao X; Zhang Z
Curr Mol Pharmacol; 2024; 17(1):e210823220109. PubMed ID: 37602543
[TBL] [Abstract] [Full Text] [Related]
14. Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Nishiyama H; Inoue T; Koizumi Y; Kobayashi Y; Kitamura H; Yamamoto K; Takeda T; Yamamoto T; Yamamoto R; Matsubara T; Hoshino J; Yanagita M;
Int J Clin Oncol; 2023 Oct; 28(10):1298-1314. PubMed ID: 37572198
[TBL] [Abstract] [Full Text] [Related]
15. Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.
Nirala BK; Yamamichi T; Yustein JT
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511127
[TBL] [Abstract] [Full Text] [Related]
16. Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mtor/HIF-1α/VEGF and EMT signalling pathways.
Zeng X; Liu S; Yang H; Jia M; Liu W; Zhu W
J Pharm Pharmacol; 2023 Nov; 75(11):1405-1417. PubMed ID: 37498992
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic value of RGS1 and mtor Immunohistochemical expression in Egyptian multiple myeloma patients; A single center study.
Hafez N; Refaat L; ElGebaly OK; Elhariry HM; Ghareeb M; Fathalla LA
PLoS One; 2023; 18(7):e0288357. PubMed ID: 37437037
[TBL] [Abstract] [Full Text] [Related]
18. LncRNA-HOTAIRM1 promotes aerobic glycolysis and proliferation in osteosarcoma via the miR-664b-3p/Rheb/mtor pathway.
Yu X; Duan W; Wu F; Yang D; Wang X; Wu J; Zhou D; Shen Y
Cancer Sci; 2023 Sep; 114(9):3537-3552. PubMed ID: 37316683
[TBL] [Abstract] [Full Text] [Related]
19. Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies.
Wang C; Dai S; Zhao X; Zhang Y; Gong L; Fu K; Ma C; Peng C; Li Y
Biomed Pharmacother; 2023 Jul; 163():114882. PubMed ID: 37196541
[TBL] [Abstract] [Full Text] [Related]
20. MiR-30 Family: A Novel Avenue for Treating bone and Joint Diseases?
Huang J; Li Y; Zhu S; Wang L; Yang L; He C
Int J Med Sci; 2023; 20(4):493-504. PubMed ID: 37057210
[TBL] [Abstract] [Full Text] [Related]
[Next]
